You should know that you are questioning the wrong audience. It's not the FDA's responsibility to make public shareholders aware of what's going on with their investment, it's Prana Biotech's. Apparently they're not ready to talk.
- Forums
- ASX - By Stock
- ATH
- SRPT Duchenne Drug trial hits 5 year mark
SRPT Duchenne Drug trial hits 5 year mark, page-54
Featured News
Add ATH (ASX) to my watchlist
|
|||||
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.28M |
Open | High | Low | Value | Volume |
0.4¢ | 0.4¢ | 0.4¢ | $6.168K | 1.542M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
39 | 52445756 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 127138639 | 21 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
39 | 52445756 | 0.003 |
63 | 91698098 | 0.002 |
30 | 126621099 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 127138639 | 21 |
0.005 | 32482632 | 30 |
0.006 | 15128927 | 24 |
0.007 | 55054408 | 29 |
0.008 | 18128275 | 22 |
Last trade - 09.59am 15/08/2024 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online